Lotus Eye Hospital and Institute credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
11.411.40.00.00.0
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
7.67.6−4.2−7.0−8.4
0.19×0.19×0.00×0.00×0.00×
0.13×0.13×−0.07×−0.12×−0.15×
3.38×3.38×0.00×0.00×0.00×
1.57×2.25×−1.21×−1.08×−1.11×
−0.43×−0.43×1.20×28.77×47.19×
16.0%16.0%0.0%0.0%0.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

LOTUSEYE₹110.00

Lotus Eye Hospital and Institute Limited

· Pharma & Health
₹ CrorePeersGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹229 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt0.00.00.011.411.4
Net Debt-8.4-7.0-4.27.67.6
Total Debt/Equity0.000.000.000.190.19
Net Debt/Equity-0.15-0.12-0.070.130.13
Total Debt/EBITDA0.000.000.003.383.38
Net Debt/EBITDA-1.11-1.08-1.212.251.57
Interest Coverage (EBIT/Interest)47.1928.771.20-0.43-0.43
Total Debt/Total Capital %0.000.000.0015.9715.97
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.